Merck Sharp + Dohme Corp.

Merck Canada Inc.

Katharine M Holloway

John A McCauley

Peter D Williams

Oscar Miguel Moradei

Thomas J Greshock

Christopher James Bungard

David Jonathan Bennett

Vouy Linh Truong

Christian Beaulieu

Carmela Molinaro

Sheldon N Crane

Satyanarayana Tummanapalli

Daniel Mckay

Karine M Villeneuve

Daniel McKay

Christian Nadeau

Daniel Simard

Helen Juteau

The present invention is directed to 2,5,6-substituted morpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

HIV protease inhibitors

The present invention is directed to 5-heteroarylmorpholine derivatives and their use in the inhibition of HIV protease, the inhibition of HIV replication, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

Growing community of inventors

Lansdale, PA, United States of America

Katharine M Holloway